SARMS MK-1775 Powder MK1755 MK 1755 AZD1775

High quality new SARMS MK-1775 Powder MK1755 MK 1755 AZD1775 CAS 955365-80-7 With best price MK 1775 is used in biological studies for the abrogation of G2/M checkpoint through WEE1 inhibition in...
Chat Now

Product Details

High quality new SARMS MK-1775 Powder MK1755 MK 1755 AZD1775 CAS 955365-80-7 With best price


MK 1775 is used in biological studies for the abrogation of G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.


Basic details:

Model No.:955365-80-7

Production Capacity:50kg/month

Delivery Date: Within 24 hours

CAS No.:955365-80-7

Molecular formula:C27H32N8O2

Grade:Pharmaceutical Grade

Storage:Shading, confined preservat...

Shipment:EMS, DHL, FedEx, TNT

Leading Time:About 5~8 working days

Means of Transport:Ocean,Land,Air

Packing:Discreet Package

Brand Name: SENDI

Purity:99%

Molecular weight:500.6

Payment Terms:Wester Union,Money Gram,Banktransfer, etc.

Certification:HSE, ISO 9001, USP, BP

Delivery Time:Within 24 hours


MK-1775 Bodybuilding Supplement

MK-1775 Ovarian Cancer

MK-1775 Muscle Growth

MK-1775 SARM Powder

MK-1775 Tumor Inhibition


Description: 

MK-1775, also known as adavosertib, AZD-1775, is a WEE1 inhibitor, is also a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.Doctors usually treat ovarian cancer with surgery. You may also have chemotherapy. Paclitaxel and carboplatin are 2 of the chemotherapy product that doctors often use to treat ovarian cancer.


Unfortunately, ovarian cancer can come back after surgery and chemotherapy. If this happens, you may have more chemotherapy. But researchers are looking for ways to improve treatment for ovarian cancer that has come back. In this trial, they are looking at a drug called MK-1775 alongside chemotherapy.MK-1775 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.


Detail Informations:

This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles. Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies.


MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancerMK-1775 treatment led to the inhibition of Wee1 kinase and reduced inhibitory phosphorylation of its substrate Cdc2. MK-1775, when dosed with GEM, abrogated the checkpoint arrest to promote mitotic entry and facilitated tumor cell death as compared to control and GEM-treated tumors. MK-1775 monotherapy did not induce tumor regressions. However, the combination of GEM with MK-1775 produced robust antitumor activity and remarkably enhanced tumor regression response (4.01-fold) compared to GEM treatment in p53-deficient tumors. Tumor regrowth curves plotted after the drug treatment period suggest that the effect of the combination therapy is longer-lasting than that of GEM. None of the agents produced tumor regressions in p53 wild-type xenografts. 


Biological Activity

MK-1775 is a potent and selective inhibitor of the tyrosine kinase WEE1 (IC50 = 5.2 nM). It selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.


Related hot sale products:

Antidepressant


Sertraline Hydrochloride


Tianeptine Sodium & Sulfate (Stablon)   

30123-17-2

Bupropion Hydrochloride

31677-93-7

Citalopram Hydrobromide

59729-32-7

Vortioxetine Hydrobromide

960203-27-4

NSI-189

1270138-40-3

Armodafinil

112111-43-0

Duloxetine hcl 抗抑郁

136434-34-9

IDRA 21

22503-72-6

Melitracen hydrochloride

10563-70-9

atomoxetine hydrochloride

82248-59-7

Doxepin hydrochloride

1229-29-4

adrafinil

63547-13-7

analgesic-antipyretic


pizotifen

15574-96-6

ibuprofen

15687-27-1

phenacetin

62-44-2

aspirin

50-78-2

propacetamol hydrochloride

66532-86-3

meloxicam

71125-38-7

Ketoprofen API

22071-15-4

aminophenazone

58-15-1

Leflunomide

75706-12-6


Sarms real photo:

SARMS.jpg


Hot Tags: sarms mk-1775 powder mk1755 mk 1755 azd1775, China, suppliers, discount, buy, bulk, pricelist, high quality, in stock

Inquiry

You Might Also Like